002001.SZ
新 和 成
SZSE · Healthcare · C 制造业 · CN
CNY 26.32
−5.39%Year over year
Reported trailing growth
- Revenue
- +2.5%
- EBITDA
- —
- EBIT
- -2.4%
- EPS
- -2.2%
- Free cash flow
- +0.9%
- Operating cash flow
- +8.5%
Forward estimates
Based on analyst estimates
- Revenue
- +13.1%
- EBITDA
- +37.0%
- EPS
- +40.7%
Three-year CAGR
- Revenue
- +11.8%
- EBITDA
- +21.2%
- EBIT
- +22.1%
- Net income
- +23.2%
- EPS
- +23.6%
- Free cash flow
- +219.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026